BETA: Please send your feedback!
Dicerna Pharmaceuticals
DRNA:NAS
Biotechnology
$0
SMALL cap
$17.90
(-0.40%)
-0.22%
since start of 2020
-10.17
About
Biotechnology
Founded 2007
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company. It is focused on the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases using its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James C. Jenson and John J. Rossi in 2007 and is headquartered in Watertown, MA.
website
Headquarters
Executives
| Name | Title | Gender |
| Roberto Guerciolini, MD, MBA | Founder | Male |
| David Michael Madden, MBA | Chairman | Male |
| John B. Green, MBA, CPA | Chief Financial Officer | Male |
| Douglas M. Fambrough, PhD | President, Chief Executive Officer & Director | Male |
| John J. Rossi, PhD | Founder | Male |
| Mark A. Behlke, MD, PhD | Founder | Male |
| James C. Jenson, PhD | Founder | Male |
| Pankaj Bhargava, MD | Chief Medical Officer | Male |
| Bob D. Brown, PhD | Chief Scientific Officer & Senior Vice President | Male |
| David W. Miller, PhD | Senior Vice President-Operations | Male |
Mindful Investing Summary
Dicerna Pharmaceuticals - Competitors and Related Companies
How Dicerna Pharmaceuticals stacks up to its peers in the Biotechnology industry or with competing business segments.
Dicerna Pharmaceuticals
DRNA:NAS
Biotechnology
$0
SMALL cap
$17.90
(-0.40%)
-0.22%
since start of 2020
-10.17
Loading…